X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds are being utilized to advance the development of Trobix's cutting-edge proprietary platform technology and to advance Precision Microbiome Oncology Therapeutics including TBX201, an oral capsule designed to alter the gut microbiome.
Lead Product(s): TBX201
Therapeutic Area: Gastroenterology Product Name: TBX201
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chartered Group
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 30, 2023
Details:
The funding will be used to advance the company’s antimicrobial resistance platform technology and to further the pre-clinical development of the its lead product, TBX101.
Lead Product(s): TBX101
Therapeutic Area: Infections and Infectious Diseases Product Name: TBX101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chartered Opus
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
